Insulin glargine (Toujeo)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Diabetes mellitus in adults and children from 6 years needing insulin (Toujeo 300 units/ml, previously Optisulin)
Product first approved 2000EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (11)
Type 1 Diabetes
NCT01689129 · Sanofi
2012-09 – 2014-04 · Type 1 Diabetes Mellitus
What this study did
NCT01683266 · Sanofi
2012-09 – 2014-03 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT02401243 · Sanofi
2015-03 – 2016-02 · Type 2 Diabetes Mellitus
What this study did
NCT02227212 · Sanofi
2014-08 – 2014-11 · Diabetes Mellitus Type 2
What this study did
NCT01676220 · Sanofi
2012-08 – 2014-03 · Type 2 Diabetes Mellitus
What this study did
Phase 2 (2)
Type 1 Diabetes
NCT01658579 · Sanofi
2012-08 – 2013-05 · Type 1 Diabetes Mellitus
What this study did
Other / comorbidity
NCT05155917 · Changhua Christian Hospital
2022-03-01 – 2024-01 · Hyperglycaemic Crisis in Diabetes Mellitus, Diabetic Ketoacidosis, Hyperglycaemic Hyperosmolar Nonketotic Syndrome
What this study did
Phase 4 (17)
Type 1 Diabetes
NCT03328845 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
2017-01-20 – 2021-11-20 · Type 1 Diabetes Mellitus
What this study did
NCT04075513 · Sanofi
2019-10-09 – 2021-09-16 · Type 1 Diabetes Mellitus
What this study did
NCT02688933 · Sanofi
2016-05-05 – 2017-06-19 · Type 1 Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT05780151 · Mira Zuidgeest
2023-07-10 – 2025-01-21 · Diabetes Mellitus, Type 2
What this study did
NCT03760991 · Sanofi
2018-12-18 – 2020-09-23 · Type 2 Diabetes Mellitus
What this study did
NCT03389490 · Elaine Chow
2018-01-01 – 2020-05-01 · Diabetes Mellitus, Type 2
What this study did
NCT04692415 · University of Split, School of Medicine
2018-12-15 – 2019-06-27 · Diabetes Mellitus, Type 2
What this study did
NCT03013985 · Emory University
2017-05-17 – 2019-03-22 · Type 2 Diabetes
What this study did
NCT02451137 · Sanofi
2015-06-16 – 2018-08-09 · Diabetes Mellitus, Type 2
What this study did
NCT02967237 · Sanofi
2016-01-04 – 2017-07-24 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT03406000 · Sanofi
2018-01-22 – 2019-02-04 · Type I Diabetes Mellitus
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Type 2 Diabetes
NCT02585674 · Sanofi
2015-12 – 2016-11 · Type 2 Diabetes Mellitus
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Glargine (Toujeo): this drugApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.